HK1087040A1 - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number
HK1087040A1
HK1087040A1 HK06107441.4A HK06107441A HK1087040A1 HK 1087040 A1 HK1087040 A1 HK 1087040A1 HK 06107441 A HK06107441 A HK 06107441A HK 1087040 A1 HK1087040 A1 HK 1087040A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treatment
metabolic disorders
agent
metabolic
Prior art date
Application number
HK06107441.4A
Other languages
English (en)
Inventor
Shalini Sharma
Borstel Reid W Von
Kirvin L Hodge
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of HK1087040A1 publication Critical patent/HK1087040A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06107441.4A 2003-08-20 2006-06-30 Compounds for the treatment of metabolic disorders HK1087040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49653303P 2003-08-20 2003-08-20
PCT/US2004/026561 WO2005018628A1 (en) 2003-08-20 2004-08-16 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
HK1087040A1 true HK1087040A1 (en) 2006-10-06

Family

ID=34216015

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107441.4A HK1087040A1 (en) 2003-08-20 2006-06-30 Compounds for the treatment of metabolic disorders

Country Status (19)

Country Link
US (1) US7906675B2 (de)
EP (1) EP1656127B1 (de)
JP (1) JP4703563B2 (de)
KR (1) KR101069276B1 (de)
CN (2) CN1835743A (de)
AT (1) ATE502631T1 (de)
AU (1) AU2004266673B2 (de)
BR (1) BRPI0413758A (de)
CA (1) CA2533890A1 (de)
DE (1) DE602004031954D1 (de)
HK (1) HK1087040A1 (de)
IL (1) IL173377A (de)
MX (1) MXPA06001963A (de)
NO (1) NO20060502L (de)
NZ (1) NZ545268A (de)
RU (1) RU2349584C2 (de)
UA (1) UA88772C2 (de)
WO (1) WO2005018628A1 (de)
ZA (1) ZA200600577B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377712A1 (pl) * 2003-02-13 2006-02-06 Wellstat Therapeutics Corporation Związki do leczenia zaburzeń metabolicznych
NZ542739A (en) * 2003-04-15 2007-02-23 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
EP1617835B1 (de) * 2003-04-30 2011-09-28 Wellstat Therapeutics Corporation Verbindungen zur behandlung von stoffwechselstörungen
EP1868595B1 (de) * 2005-04-01 2012-01-11 Wellstat Therapeutics Corporation Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
AU2007208125B2 (en) * 2006-01-25 2012-04-05 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087506A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637375A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1978948A4 (de) * 2006-02-02 2010-06-16 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US8044243B2 (en) * 2006-02-13 2011-10-25 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
NZ570100A (en) * 2006-02-28 2011-01-28 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
CN101410105A (zh) * 2006-03-31 2009-04-15 维尔斯达医疗公司 代谢紊乱的组合治疗
MX2008014560A (es) * 2006-05-18 2008-11-28 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
JP5252585B2 (ja) * 2006-06-09 2013-07-31 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
EP2240024A4 (de) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CN109096350B (zh) * 2017-09-21 2020-07-28 暨南大学 辣木籽中新的硫醚类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (de) 1964-07-28 1967-05-02
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
EP1556085A4 (de) 2002-11-01 2012-08-22 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselst rungen
PL377712A1 (pl) 2003-02-13 2006-02-06 Wellstat Therapeutics Corporation Związki do leczenia zaburzeń metabolicznych
NZ542739A (en) 2003-04-15 2007-02-23 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2004093806A2 (en) 2003-04-22 2004-11-04 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1617835B1 (de) 2003-04-30 2011-09-28 Wellstat Therapeutics Corporation Verbindungen zur behandlung von stoffwechselstörungen

Also Published As

Publication number Publication date
KR101069276B1 (ko) 2011-10-04
AU2004266673A1 (en) 2005-03-03
EP1656127A1 (de) 2006-05-17
NZ545268A (en) 2009-05-31
US7906675B2 (en) 2011-03-15
JP4703563B2 (ja) 2011-06-15
RU2006108572A (ru) 2006-07-27
MXPA06001963A (es) 2006-05-31
WO2005018628A1 (en) 2005-03-03
CN101948416A (zh) 2011-01-19
IL173377A0 (en) 2006-06-11
JP2007502824A (ja) 2007-02-15
DE602004031954D1 (de) 2011-05-05
UA88772C2 (ru) 2009-11-25
US20070282003A1 (en) 2007-12-06
ZA200600577B (en) 2007-01-31
AU2004266673B2 (en) 2010-08-05
KR20060066730A (ko) 2006-06-16
EP1656127B1 (de) 2011-03-23
IL173377A (en) 2012-12-31
CA2533890A1 (en) 2005-03-03
RU2349584C2 (ru) 2009-03-20
CN1835743A (zh) 2006-09-20
NO20060502L (no) 2006-05-03
BRPI0413758A (pt) 2006-10-31
EP1656127A4 (de) 2009-04-29
ATE502631T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
HK1087040A1 (en) Compounds for the treatment of metabolic disorders
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
DE60112974D1 (en) Carbolinderivate
IL179728A0 (en) Indoles useful in the treatment of inflammation
GB0225475D0 (en) Therapeutic agents
MY137250A (en) Method of treatment of transplant rejection
GB0318447D0 (en) Therapeutic agents
IL179607A0 (en) Indoles useful in the treatment of inflammation
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
UA84156C2 (ru) Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
DE60216233D1 (en) Carbolinderivate
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
TW200510317A (en) Caspase inhibitors and uses thereof
PH12009500610A1 (en) 4-imidazolin-2-one compounds
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
WO2005005415A8 (en) Indoles useful in the treatment of inflammation
MXPA04006041A (es) Antivirales de piridoquinoxalina.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AP2001002306A0 (en) Bridged piperazine derivatives.
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
SE0101082D0 (sv) Novel use
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150816